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Saturation analysis for whole-genome bisulfite 
sequencing data
To the Editor:
Whole-genome bisulfite sequencing (WGBS) 
has become an integral part of basic and 
clinical research and has been widely used to 
generate reference methylomes since 2010 
(refs. 1,2). However, because of the initial 
high cost of a 30× WGBS methylome3, no 
saturation analysis has been performed to 
assess the information that can be harnessed 
from individual methylome features at 
different sequencing coverage. Consequently, 
the International Human Epigenome 
Consortium (IHEC; http://ihec-epigenomes.
org/research/reference-epigenome-
standards/) decided to sequence reference 
methylomes to 30× coverage, which was 
believed to adequately capture the majority 
of the methylation signal for subsequent 
analyses.
Here, we report the first saturation analysis 
for WGBS. We assessed the effect of coverage 
on the identification of five features that reveal 
key aspects of the methylome, including 
informative CpG sites (iCGs), differentially 
methylated positions (DMPs), differentially 
methylated regions (DMRs), blocks of 
comethylation (COMETs) and differentially 
methylated COMETs (DMCs). We carried 
out a downsampling analysis by sequentially 
removing random WGBS reads—thereby 
reducing coverage—to assess the loss of 
information for each of the above features 
related to coverage, resolution and complexity. 
Individual CpG methylation states, defined 
by iCGs, and methylation changes, defined 
by DMPs, exhibited the highest (single 
base) level of resolution and lowest level of 
complexity. In contrast, COMETs and DMCs 
had the lowest resolution and highest levels 
of feature complexity, whereas DMRs had 
medium resolution and complexity. On the 
basis of this analysis, we show that the current 
reference methylome coverage (30×) results 
in ~50% loss of DMPs and is therefore only 
of limited use for high-resolution feature 
analysis (e.g., DMPs).
We analyzed 13 WGBS methylomes 
(M1–13), which are summarized 
in Supplementary Table 1 and 
Supplementary Methods4. Except for 
M13, all methylomes were generated 
by the Roadmap Epigenomics5 (http://
www.roadmapepigenomics.org/) and 
BLUEPRINT6 (http://www.blueprint-
epigenome.eu/) projects. The same 
methylomes were also used in a parallel 
study4 describing the COMET, DMC 
and information recovery analyses. To 
our knowledge, M1–3 are the deepest 
methylomes reported to date and thus 
constitute particularly valuable references  
for future studies.
Downsampling is the method of choice 
for saturation analysis and assessing 
coverage-dependent information loss. 
It requires a static reference methylome 
against which to downsample a deep-
coverage test methylome. Better results are 
obtained if both methylomes are available in 
multiple replicates as described below. For 
the static reference, we evaluated two pre-
IHEC (i.e., created before the consortium 
and its guidelines were established) (M4 
(ref. 7), M13 (ref. 8) and four IHEC (M7–
10) methylomes (Fig. 1) and selected the 
superior IHEC replicates M7–10 (derived 
from human embryonic stem cells and 
generated by the Roadmap Epigenomics 
Project) against which to downsample deep-
coverage test replicates M1–2 (derived from 
purified human monocytes and generated 
by the BLUEPRINT Project). For each 
of the five features described above, the 
test methylomes (M1–2) were randomly 
downsampled to different read-coverage 
levels and assessed for information loss 
by comparison to the static reference 
methylomes (M7–10). For the analysis 
of iCGs, DMPs and DMRs, we used 
BSmooth9 and RADmeth10, and we used 
COMETgazer4 and COMETvintage4 for the 
analysis of COMETs and DMCs (https://
github.com/rifathamoudi/COMETgazer). 
Figure 2a shows the saturation analysis of 
iCGs, DMPs, DMRs, COMETs and DMCs 
for M1–2 by downsampling from 83× or 91× 
to 5× sequence coverage. For each coverage 
and feature, the respective percentages of 
retained information are plotted on the y 
axis. The total number of M1–2 features 
Figure 1  Single-replicate analysis. (a) Saturation analysis of DMP calling decay of monocyte methylome 
(M1) versus pre-IHEC (M4, M13) and IHEC (M3, M6–7, M9–11) methylomes using Fisher’s Exact Test. 
(b) Saturation analysis of all differential methylation features using M1–2 and M3, M7–10. Single-
replicate DMP calls (M1 versus M3) and replicate RADmeth analysis show a different decay and a 
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The increased resolution and coverage 
of WGBS enables the identification of 
genome-wide DMPs, as exemplified by 
the identification of dynamic CpG sites 
through analysis of over 40 WGBS data 
sets6. Because our saturation analysis 
reveals that DMP calling at ~30× coverage 
captured only ~50% of DMPs in a replicate 
analysis, we next investigated whether part 
of the lost information could be recovered 
through RRBS spike-in. As DMP loss 
occurs frequently in CpG-rich sequences, 
we spiked simulated RRBS (M14–15) 
into WGBS (M1–M2) data, resulting in 
a quantitative DMP recovery of 5% at 
30× and ~12% at 10× (Fig. 3). Figure 3 
can be used as a guide to estimate DMP 
information gain for spiking RRBS into 
WGBS at different coverage.
We report the first saturation analysis 
for WGBS-based methylomes that has 
implications for subsequent feature 
analyses of the reference methylomes 
generated by the Roadmap Epigenomics 
Project12, BLUEPRINT13 and other 
members of the International Human 
Epigenome Consortium (http://www.
ihec-epigenomes.org/). Our results 
demonstrate that methylomes generated 
at 30× coverage and single replicates were 
not adequate for quantitative identification 
of DMPs, arguably the most desirable 
feature of WGBS methylome analysis. To 
improve detection of methylation features 
from existing data, we have developed 
called at highest coverage against M7–10 
was set to 100%. Whereas 95% of iCGs were 
retained at the current reference methylome 
coverage of 30×, only 50% of the 757,623 
DMPs called at maximum coverage were 
called in double replicate analysis using 
RADmeth (Fig. 2a) and 45% in single-
replicate analysis using Fisher’s exact test 
(Fig. 1b; χ2, P < 0.0001). A 45–50% DMP 
loss was confirmed using other reference 
methylomes (M7–10 or M11–12; Fig. 2b). 
This loss of information has not previously 
been reported for methylome analyses at 
30× coverage. In comparison, the higher 
complexity (but lower resolution) DMRs, 
COMETs and DMCs retained 85–95% of 
the information. At 10× coverage ~77% and 
~85% of DMC and COMET information, 
respectively, was retained compared to 
only ~40% for DMRs. Notably, using first 
derivatives, the information loss started at 
~85× for DMPs and ~8× for DMCs (Mann-
Whitney, P < 0.0001) (Supplementary 
Methods, statistical analysis).
The main advantage of WGBS over less 
expensive enrichment-based methods, such 
as methylated DNA immunoprecipitation 
sequencing (MeDIP-seq)11 is the ability 
to detect DNA methylation at single-base 
resolution. MeDIP-seq allows detection 
only of DMRs but not of DMPs. Whereas 
reduced representation bisulfite sequencing 
(RRBS)5 also has single-base resolution and 
thus allows detection of DMPs, it covers 
only ~10% of the methylome, mostly in 
CpG-rich regions, such as CpG islands. 
two algorithms (COMETgazer4 and 
COMETvintage4) that enable partial 
recovery of the lost information, even at 
low (5×) coverage. These methods require 
two methylome replicates, indicating that 
replicates are more important than coverage 
in terms of maximizing the accuracy of 
signal that can be identified from the 
data. Currently, IHEC standards allow 
single-replicate methylomes and 60% of 
current IHEC methylomes are in fact single 
replicates. On the basis of the results of this 
saturation analysis, we recommend multiple 
replicates for future methylome sequencing.
Note: Any Supplementary Information and Source Data 
files are available in the online version of the paper 
(doi:10.1038/nbt.3524).
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Figure 2  Saturation analysis of deep replicate methylomes. (a) Downsampling of methylome features for 
deep M1–2 against static M7–10. The analysis was conducted with RADmeth for DMPs, BSmooth for 
DMRs and COMETvintage for DMCs. (b) Replicate DMP analysis for deep M1–2 against static M7–10 or 
M11–12 reference methylomes, as calculated by RADmeth. This represents two independent analyses as 
combined results showing DMP analysis variation (shaded standard error). Downsampling iterations were 
run for each of the selected features by shrinking coverage by 5% for each downsampling from 100% 
to 5% of the data. The absolute deviation from feature calls at 100% is represented as percentage 
values. Colored Loess curve and shaded standard error provide estimates of information retained at each 
coverage across all iterations.



























Figure 3  RRBS spike-in simulation. WGBS 
methylomes (M1–M2) were downsampled and 
spiked-in with static ~90× RRBS simulated 
data sets (M14–M15). Replicate DMP analysis 
of M1–2 versus M7–8 was performed using 
RADmeth. The percentage (%) information 
rescued reports the percentage difference in 




























NATURE BIOTECHNOLOGY   VOLUME 34   NUMBER 7   JULY 2016 693
COMPETING FINANCIAL INTERESTS
The authors declare competing financial interests: 
details are available in the online version of the paper 
(doi:10.1038/nbt.3524).
Emanuele Libertini1, Simon C Heath2,  
Rifat A Hamoudi3, Marta Gut2,  
Michael J Ziller4–6, Javier Herrero7, Agata Czyz8,  
Victor Ruotti8, Hendrik G Stunnenberg9,  
Mattia Frontini10–12, Willem H Ouwehand10–13, 
Alexander Meissner4–6, Ivo G Gut2 &  
Stephan Beck1
1Medical Genomics, UCL Cancer Institute, 
University College London, London, UK. 2Centro 
Nacional de Análisis Genómico (CNAG), Parc 
Científic de Barcelona, Barcelona, Spain. 3Division 
of Surgery and Interventional Science, University 
College London, London, UK. 4Broad Institute of 
MIT and Harvard, Cambridge, Massachusetts, 
USA. 5Harvard Stem Cell Institute, Cambridge, 
Massachusetts, USA. 6Department of Stem Cell 
and Regenerative Biology, Harvard University, 
Cambridge, Massachusetts, USA. 7Bill Lyons 
Informatics Centre, UCL Cancer Institute, 
University College London, London, UK. 8Illumina 
Inc., San Diego, California, USA. 9Department 
of Molecular Biology, Radboud University 
Nijmegen, Nijmegen, Netherlands. 10Department 
of Haematology, University of Cambridge, 
Cambridge, United Kingdom. 11National Health 
Service Blood and Transplant, Cambridge 
Biomedical Campus, Cambridge, UK. 12British 
Heart Foundation Centre of Excellence, University 
of Cambridge, Cambridge, UK. 13Wellcome 
Trust Sanger Institute, Wellcome Trust Genome 
Campus, Hinxton, Cambridge, UK.  
e-mail: emanuele.libertini@ucl.ac.uk or  
s.beck@ucl.ac.uk
Published online 27 June 2016;  
doi:10.1038/nbt.3524
1. Bock, C. et al. Nat. Biotechnol. 28, 1106–1114 
(2010).
2. Harris, R.A. et al. Nat. Biotechnol. 28, 1097–1105 
(2010).
3. Beck, S. Nat. Biotechnol. 28, 1026–1028 (2010).
4.  Libertini, E. et al. Nat. Commun. 7, 11306 (2016).
5. Gu, H. et al. Nat. Protoc. 6, 468–481 (2011).
6. Ziller, M.J. et al. Nature 500, 477–481 (2013).
7. Lister, R. et al. Nature 462, 315–322 (2009).
8. Li, Y. et al. PLoS Biol. 8, e1000533 (2010).
9. Hansen, K.D., Langmead, B. & Irizarry, R.A. Genome 
Biol. 13, R83 (2012).
10. Dolzhenko, E. & Smith, A.D. BMC Bioinformatics 15, 
215 (2014).
11. Down, T.A. et al. Nat. Biotechnol. 26, 779–785 
(2008).
12. Satterlee, J.S., Schübeler, D. & Ng, H.H. Nat. 
Biotechnol. 28, 1039–1044 (2010).
13. Adams, D. et al. Nat. Biotechnol. 30, 224–226 
(2012).
How China can enhance adoption 
of biotech crops
To the Editor:
The development of new approaches for 
creating genetically modified (GM) crops 
continues apace, yet societal and public 
policy decisions slow or prevent their 
adoption. This is unfortunate, especially 
in China, which has so much to gain and 
has done much to harness the power of 
biotech for the public good. China, the 
most populous country in the world, was 
until recently classified as a developing 
country1. As migration from the rural to the 
urban areas continues, and a burgeoning 
middle-class is developing, food security 
and environmental stewardship have 
become national goals. GM crops should be 
part of the solution. However, the voices of 
anti-GM groups have become louder and 
more difficult for the government to ignore, 
so officials have been cautious in promoting 
GM technology and implementing its 
adoption. In the “No. 1 Central Document” 
published in January, the government 
touted “agricultural modernization” with 
a push to “more efficient, inclusive and 
environment-friendly” farming. With 
respect to implementation of GM products, 
we believe the government should be doing 
more, not only for its own people but also 
as a world leader affecting global policy for 
agricultural innovation. For that to happen, 
two important needs should be integrated 
into policy.
First, efforts aiming to develop GM 
crops should be focused on balancing the 
benefits to the producer, consumer and 
environment. Currently, the traditional sole 
focus of increasing yield is inappropriate2,3; 
this must be expanded to include 
production of high-quality, safe and low-
cost food, produced in an environmentally 
responsible manner. The Chinese 
government has already stated this in its 
“No. 1 Central Document.” Therefore, GM 
technology that reduces pesticide and labor 
inputs fits in well with this government 
charge. Advances in gene editing may even 
supplant the more traditional forms of 
genetic engineering. A successful example 
of editing was demonstrated with hexaploid 
bread wheat4,5 that was developed by 
Chinese scientists for the domestic market. 
Investment in Chinese biotech can also 
help develop the appropriate biotech 
products for the world market that will 
have consumer and environmental benefits, 
as well helping other countries build their 
scientific capacity.
Second, equally if not more important, 
is the need for the Chinese government 
to develop a committed and well-funded 
educational program on biotech for the 
public. Several recent studies indicate that 
an increasing proportion of the Chinese 
public opposes GM technology6,7. The 
increased frequency of food safety scandals 
in China has caused consumers to be more 
wary of their food and more skeptical 
of the government; and with so much 
misinformation readily available about 
GM, biotech crops may become collateral 
damage. Custom-designed educational 
programs are urgently needed to educate 
consumers about the safety of GM crops 
and the foods derived from them. We 
appeal to the government to develop such 
programs and increase public dialog. 
Chinese scientists will be key in this effort 
because they have the most knowledge 
about biotech and are trusted by the general 
public. Additionally, they are best able to 
identify and correct the misinformation, 
spread by anti-science groups opposed to 
GM crops, which permeates some of the 
news media. It is important that researchers 
gain the confidence of the public so public 
policies on GM crops and biotech can move 
forward.
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